

How PrismRA® Ensures Optimal Therapy is Prescribed for Rheumatoid Arthritis Patients

A Physician Experience Story



In traditional rheumatoid arthritis treatment, patients typically wait at least **six months** after starting a new medication to determine whether it is working.

Problem:



Some data report that patients stay on their medication for approximately **280 days**.¹




Drug non-response costs U.S. healthcare system **\$20 billion** annually and can even lead to worse patient outcomes as further joint damage can occur while providers wait to see if a medicine might eventually reduce symptoms.^{2,3}



Solution:



Scipher Medicine's PrismRA is a molecular signature test that informs therapy selection based on the likelihood of success for the individual patient.



Physicians order PrismRA for their patients who are considering starting or modifying treatment.



The PrismRA test may be used by providers whenever understanding a patient's predicted poor response to commonly prescribed medications would be useful before starting or modifying treatment.



The PrismRA test can determine if a patient will respond to a drug class known as tumor necrosis factor (TNF)- α inhibitor therapies. Being able to guide treatment in that manner can eliminate months of guesswork for the physician and needless degeneration, pain and expense for the patient. It allows doctors to make rational choices about which medication to progress to at the correct stage in RA treatment.

1. Curtis JR, et al. 12-Month Treatment Outcomes of Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor- α Inhibitor Therapies. Scientific poster accepted by ACR, to be presented November 2021.

2. The IQVIA Institute. (2020). Global Medicine Spending and Usage Trends: Outlook to 2024. The IQVIA Institute for Human Data Science. <https://www.iqvia.com/>.

3. Personalized Medicine Coalition. (2017). The Personalized Medicine Report: 2017-Opportunity, Challenges, and the Future. The Personalized Medicine Coalition (PMC). <https://personalizedmedicinecoalition.org>

Outcome:

Robert Levin, MD, has been practicing rheumatology in Clearwater, Florida since 1989. He uses Scipher Medicine's PrismRA biomarker (or RNA expression) test in his practice to help guide his patients towards a treatment plan best aligned with their own unique biology for optimal success.



■ PrismRA is a useful tool to help us figure out what might be a better choice when we're working with a patient who's ready to start advanced treatment. I try to use it before we pick the first biologic treatment, because it lets us know if the patient will respond to a TNF inhibitor or not. **We've never had a test that helped us choose a medication that will be more effective, and that's really exciting.** We're able to make rational decisions about next steps in care rather than throwing darts at a board.

I try to order it relatively early in the treatment process, so the results are waiting when we're ready to move to that next phase of treatment. I want to make sure we have that insight when it's time to move the patient to the next stage. It's in the patient's best interest to have the information as early as possible. The patient is understanding and accepting of the need to get the test done and then hold onto the results until we need them.

Just as it is with any treatment, patients are often initially concerned about safety and tolerability, and if they can pay for the test and recommended treatment. When they find out that the test can improve the effectiveness of their treatment, and that it is based on their specific molecular signature, they're usually eager to proceed. Adding personalized medicine to the treatment plan helps give them the peace of mind that we're trying to select the treatment plan that will work best for them.

This is a huge advancement in the treatment of RA. I hope everyone adopts PrismRA, both doctors and insurance providers, as the traditional therapies aren't always successful. Our ultimate goal is always the patient's well-being and treatment success. **In my practice, PrismRA helps deliver positive outcomes in an easy-to-administer test.**

The Scipher Medicine team is also a great partner in our practice's success. They worked with us on establishing a system to order tests and get results back in the optimal time frame to guide the next steps of treatment. ■■

To bring the test into your practice, contact **Provider Relations** at **855-724-7437** or **provider_relations@scipher.com**.

